An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis

Purpose To design an updated vancomycin dosing protocol for initiating therapy in patients undergoing chronic intermittent high-flux hemodialysis (iHFHD) that is congruent with the revised 2020 consensus guidelines for therapeutic drug monitoring (TDM). Methods Monte Carlo simulation methods were used to study vancomycin dosing for patients on iHFHD. Vancomycin regimens were constructed as intravenous infusions (for intradialytic administration) of a loading dose and maintenance doses 3 times weekly during subsequent dialysis sessions. Vancomycin plasma concentrations were simulated, and the probability of target attainment (PTA) for a 24-hour area under the time-concentration curve (AUC(24)) of 400 to 700 mg center dot h/L was determined. Standardized weight-based (ie, dose-banding) regimens were investigated, and an optimized protocol was selected based on TDM target attainment and practical considerations for use in the dialysis setting. Results The proposed vancomycin dosing protocol (for intradialytic administration) specifies 3 regimens: (1) a 1,500-mg loading dose and 750-mg maintenance doses for patients weighing 50 kg to 69 kg; (2) a 2,000-mg loading dose and 1,000-mg maintenance doses for patients weighing 70 kg to 89 kg; and (3) a 2,500-mg loading dose and 1,250-mg maintenance doses for patients weighing 90 kg to 110 kg. In a simulated hemodialysis population (n = 5,000), the proposed protocol delivered median (interquartile range [IQR]) loading and maintenance doses of 25.0 (23.4-26.6) mg/kg and 12.5 (11.8-13.3) mg/kg, respectively. The PTA for an AUC(24) of 400 to 700 mg center dot h/L was 74.7% on day 1 and 70.8% on day 8, with less than 10% of values exceeding the target range. Conclusion Our proposed dosing protocol for patients undergoing iHFHD offers an updated and practical approach for initiating vancomycin therapy that can be optimized with early TDM.

Automated summary

The study developed an updated vancomycin dosing protocol for chronic intermittent high-flux hemodialysis patients based on Monte Carlo simulation methods and therapeutic drug monitoring guidelines. Different regimens were constructed for patients of varying weights to achieve target vancomycin plasma concentrations during dialysis sessions. The proposed protocol demonstrated high probability of target attainment and practical applicability in the dialysis setting.